Skip to content

Efficacy of Proscure on dysmenorrhea

Efficacy of Proscure capsule on dysmenorrhea in known cases of endometriosis

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20211201053241N1
Enrollment
90
Registered
2022-01-01
Start date
2021-12-21
Completion date
Unknown
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endimetriosis. Endometriosis of uterus

Interventions

Intervention 1: Intervention group: Women 20 to 45 years old with dysmenorrhea due to endometriosis
The intervention is the prescription of Proscore drug produced by Gol Daroo company that the patient consumes morning and night in clean days. First, the pain and quality of life questionnaire is fill

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Definite diagnosis of Endometriosis Gynecological refer VAS bigger than or equal 3 No need to emergency management Age between 20-45

Exclusion criteria

Exclusion criteria: Wish to pregnancy in 3 months later breast feeding need to emergency no attempt to herbal medicine

Design outcomes

Primary

MeasureTime frame
Dysparunia based on VAS questionare. Timepoint: The beginning of the study and then the end of the study at the end of three months of treatment. Method of measurement: VAS questionaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Akhtari

Iran University of Medical Sciences

Eli.akhtari@gmail.com+98 21 5563 9667

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026